Neuron-Specific EV Isolation via Novel Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating cell-type specific extracellular vesicles (EVs), particularly brain-specific and neuron-specific EVs, are hindered by the heterogeneity and low abundance of EVs in biological samples, as well as the lack of suitable quantification and purification methods.
Innovation Solution
The discovery of novel biomarkers listed in Tables 1-5, which are specifically expressed in brain-specific and neuron-specific EVs, allows for the isolation of these EVs from human biological samples such as cerebrospinal fluid (CSF) or plasma, using methods like immuno-isolation and mixed-mode chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If L1CAM is used as a marker for neuron-derived EVs, then EV isolation is enabled, but specificity is reduced due to wide expression outside the brain
Solution Approach 1:
The patent extracts and identifies novel neuron-specific markers (such as SYT1, SYP, and other synaptic vesicle proteins) that are exclusively or predominantly expressed in neurons, replacing the non-specific L1CAM marker. This extraction of highly specific markers from the complex EV population enables precise isolation of neuron-derived EVs without contamination from other cell types.
Solution Approach 2:
The patent applies local quality by selecting markers with different specificity levels for different applications. Highly specific markers like SYT1 are used when maximum neuron-specific isolation is required, while other markers may be used when broader neural cell isolation is acceptable. This localized optimization of marker selection resolves the contradiction between isolation efficiency and specificity.
2Quantity of substance
If total EV population is isolated from plasma, then quantity of EVs is increased, but cell-type specific information is lost
Solution Approach 1:
The patent uses cell-type specific markers (such as SYT1 for neurons, GFAP for astrocytes, MBP for oligodendrocytes) as intermediaries to bridge the gap between total EV isolation and specific cell-type enrichment. These markers serve as mediators that enable selective capture of EVs from specific cell types while maintaining sufficient quantity for downstream analysis, thus preserving cell-type origin information.
Solution Approach 2:
The patent segments the total EV population into distinct cell-type specific subsets using multiple markers targeting different cell types. By applying segmentation through multi-marker approaches, the patent simultaneously achieves sufficient quantity for each subset while preserving the cell-type origin information that would be lost in bulk isolation.
3Ease of operation
If EVs are isolated from limited biosample volumes, then non-invasive sampling is maintained, but EV quantity and concentration are reduced
Solution Approach 1:
The patent applies parameter changes by optimizing multiple variables including marker selection (using high-affinity antibodies against neuron-specific markers), incubation conditions (temperature, time, buffer composition), and isolation methodology (magnetic bead-based vs. other approaches). These parameter optimizations maximize EV recovery and concentration from limited sample volumes while maintaining the non-invasive sampling advantage.
Solution Approach 2:
The patent replaces traditional mechanical isolation methods (such as ultracentrifugation requiring large volumes) with immunomagnetic separation techniques that use antibody-antigen binding chemistry to concentrate EVs from small volumes. This substitution of chemical binding mechanisms for mechanical separation enables efficient EV isolation from limited biosamples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the effective isolation and analysis of brain-specific and neuron-specific EVs, providing a non-invasive means to assess brain health and potentially aid in the early detection of neurodegenerative diseases.
Implementation Method 1
isolating the cell type-specific and/or organ-specific extracellular vesicles based on the presence of a biomarker on the surface of the extracellular vesicles
Implementation Method 2
using methods like immuno-isolation and mixed-mode chromatography
Data Source
AI summary
The present invention relates to novel biomarkers and combinations thereof for cell type-specific and/or organ-specific extracellular vesicles, in particular, brain-specific and/or neuron-specific extracellular vesicles. The present invention also provides methods for isolation and/or enrichment of cell type-specific and/or organ-specific extracellular vesicles, methods for identification of extracellular vesicles derived from a cell, and methods for diagnosing or prognosing a disorder, e.g., a neurodegenerative disorder, using the cell type specific and/or organ-specific extracellular vesicles. Compositions in the form of kits of reagents for detecting the cell type-specific and/or organ-specific extracellular vesicles are also provided.